We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Technology StocksInvesting in Exponential Growth

Previous 10 Next 10 
From: Paul H. Christiansen2/11/2020 3:28:28 PM
   of 1028
AI-formulated medicine to be tested on humans for the first time

A drug designed entirely by artificial intelligence is about to enter clinical human trials for the first time. The drug, which is intended to treat obsessive-compulsive disorder, was discovered using AI systems from Oxford-based biotech company Exscientia. While it would usually take around four and a half years to get a drug to this stage of development, Exscientia says that by using the AI tools it's taken less than 12 months.

The drug, known as DSP-1181, was created by using algorithms to sift through potential compounds, checking them against a huge database of parameters, including a patient's genetic factors. Speaking to the BBC, Exscientia chief executive Professor Andrew Hopkins described the trials as a "key milestone in drug discovery" and noted that there are "billions" of decisions needed to find the right molecules for a drug, making their eventual creation a "huge decision." With AI, however, "the beauty of the algorithm is that they are agnostic, so can be applied to any disease."

Read More - Engadget

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/11/2020 3:33:49 PM
   of 1028
Cloud data platform giant Snowflake raises $479M at $12.4B valuation, partners with Salesforce

Data warehousing startup Snowflake Computing announced a $479 million funding round that gives the cloud company a whopping $12.4 billion valuation.

Dragoneer Investment Group — a backer of Airbnb, Slack, Spotify, Uber and other giants — led the Series G round and Salesforce Ventures participated for the first time. Snowflake also announced a new partnership with Salesforce; details of that deal will be announced in June.

Read More - GeekWire

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/11/2020 3:38:53 PM
   of 1028
Here are Disney’s hurdles in becoming an international streaming sensation

Walt Disney Co. breezed past analysts’ estimates for its new Disney+ streaming service, which was unveiled in November.

Still, there are a few hurdles that remain before Disney DIS, -1.16% can be considered a global sensation. The Burbank, Calif.-based company may be the world’s most recognized media brand, but it’s not immune to the challenges of the over-the-top (OTT) television environment, especially for subscription video on demand (SVOD).

Chief Executive Officer Robert Iger, in the first earnings report since the company released Disney+, said Tuesday it got 26.5 million subscribers through the end of December. Growth continued in the current quarter, with another 2 million subscribers added, bringing the total to 28.6 million. To put that number in perspective, Hulu recently passed 30 million subscribers despite launching 12 years ago.

Read More Market Watch

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/11/2020 3:47:21 PM
   of 1028
Five Takeaways From the FTC’s New Antitrust Probe

Much of the antitrust scrutiny on big tech companies has focused on whether their biggest acquisitions violated competition laws. Now the Federal Trade Commission, in a sweeping review of five iconic players in the industry, is looking at whether their smaller deals might have hurt competition, too.

On Tuesday, the FTC said it has ordered the five companies—including Apple, Facebook, Amazon, Microsoft and Alphabet, the parent company of Google—to provide details and documents about the acquisitions they completed between the beginning of 2010 and the end of 2019. The agency is looking strictly at deals that the companies didn’t previously report to antitrust regulators under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, a federal law that requires companies to file details about proposed mergers that meet certain requirements.

Here are five takeaways from the FTC’s announcement:

Read More - $ The Information

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/12/2020 10:06:49 AM
   of 1028
Preparing for a Digital Transformation in Manufacturing

Most CEOs understand they are in a race to implement artificial intelligence

Last year, the Association for Advancing Automation (A3) surveyed our members about their companies’ adoption of AI. More than 76% of respondents felt that AI will be important to their companies in the next 3 years. However, just 3.3% of those surveyed said that AI was being widely applied in their organizations.

This has been called the Ambition-Execution Gap.

Companies know they need to implement AI strategies but are frequently at a loss on where to begin. Or they get stuck in a pilot purgatory where AI initiatives never reach a scale where they can help the overall enterprise. Even when on the right track, there’s not the talent in the pipeline to support their efforts.

Read More – Association for Advancing Automation

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/13/2020 3:26:49 PM
   of 1028
PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants

Has the subsequent selloff been irrational?

On Tuesday of this week PTE made the above announcement after the market closed. On Wednesday, PTE opened at $1.75 per share, down 45% from the previous day’s close. For the day, more than 7 million shares traded, almost all within a small variance of $1.70 per share.

The sell-off was probably expected: traditional Wall Street thinking dictates that investors should sell whenever existing shares are exposed to dilution.

However, one has to wonder if those selling their shares bothered to read the following - Our Vision – which is taken verbatim from a separate registration statement filed with the SEC and which will be included in the final Prospectus.

The section Where You Can Find More Information offers instructions on how to obtain that information.

Here is PTE’s Our Vision:

We aspire to be a global biotechnology company that provides superior, tangible, and pragmatic platform technologies that provide superior results to patients, while reducing costs and promoting improved health economics for patients, providers, and payors. We believe this can be accomplished through our pursuit of complex simplicity, which embodies the development of robust cell/tissue-derived therapies that can be efficiently produced and deployed. PolarityTE is committed to delivering transformative technology that positively impacts humanity.

PolarityTE was founded by a dedicated group of doctors and scientists from The Johns Hopkins University School of Medicine, who left to become part of something bigger. Something that could transform the future of medicine. We believe that living systems require more than a simple singular input (for example a growth factor, stem cell, or nano-particle), to produce a complex output. Therefore, we took a different direction and developed multi-tiered platform technologies that propagate the necessary complex substrate required for regenerating fully-functional tissue, such as skin, bone, cartilage, muscle, blood vessels, and neural elements, as well as solid and hollow organ composite tissue systems. We have engineered and developed our regenerative materials and core tissue substrate technology platforms to allow us to induce, maintain, and promote the integrated polarity, organized assembly, and interface development of cells and tissues, so that they replicate regenerative healing in the body and are not seen as foreign by the immune system.

The core technology of TE products is minimally polarized functional units (“MPFUs”) consisting of self-complexing intelligent regenerative materials (“SCIRM”). SCIRM within an MPFU form polarizing, multi-cellular aggregates that act as an intrinsic, regenerative bio-reactor capable of expanding, proliferating, and synthesizing cells, materials, factors, or systems necessary for regenerating full-thickness, three-dimensional tissue. The TE products we develop begin with the patient’s own tissue to produce SCIRM that address the specific tissue or system needed for the patient’s care. Our product pipeline focuses on the development of regenerative products for a variety of tissue types and organ systems that are commonly altered, injured, or destroyed by a variety of diseases, pathologies, traumatic events, and medical interventions.

SkinTE, our first tissue product, was registered with the United States Food and Drug Administration (FDA) in August 2017, and is now commercially available for the repair, reconstruction, replacement, and regeneration of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. We are pursuing a regional plan for commercial rollout that began in late October 2018, and at the beginning of January 2019 we had 24 sales representatives in the field marketing SkinTE.

OsteoTE is designed to utilize the patient’s bone to repair, reconstruct, replace, supplement, or regenerate bone damage or defects. We registered OsteoTE with the FDA in December 2018. We are preparing for the first application of the product in a clinical setting, which we are endeavoring to achieve in the first half of 2019.

Human cells, tissues and cellular and tissue-based products (“HCT/Ps”) are governed by specific FDA regulations that provide for a registration pathway that is different than the pathway for traditional drug candidates. SkinTE and OsteoTE are both registered as HCT/Ps under Section 361 of the Public Health Service Act.

We have a number of additional TE products under development, including the following:

· AdipoTE to optimize the delivery of autologous fat beyond the capabilities of current fat transfer techniques utilized in procedures on, among others, the breast, buttocks, and face;

· AngioTE to address vascular regeneration including microscopic capillary networks all the way up to great vessel replacement;

· NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures;

· UroTE targeting the delivery of autologous urogenital epithelium and submucosa across a spectrum of diseases and processes, including urethral strictures, urethral creation, bladder reconstruction, and ureter reconstruction;

· LiverTE to address numerous causes of liver failure, including NASH, fibrosis/cirrhosis, surgical resection of the liver; and

· BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue.

RTD and ARC represent research and development of new science and product opportunities based on what we learned while developing the TE platform. RTD is focused on altered state analytes for the generation of composite materials that can be utilized for the augmentation, modulation, and regulation of cell and tissue-derived systems. ARC is focused on the design and development of gene transfer, small molecule synthesis, composite therapeutics, and alteration of self-propagating cell/tissue-derived bioreactors.

We have significant research facilities and a well-educated and skilled team of scientists and researchers. These resources are highly beneficial to the work we are doing on our TE products and in RTD and ARC. We also offer research services to unrelated third parties on a contract basis, which we offer under the trademark POLARITYRD. Contract research services help us defray the costs of maintaining a first-rate research facility and allow us to meet companies pursuing new technologies that may be opportunities for collaborative or strategic relationships going forward.

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/14/2020 12:13:53 PM
1 Recommendation   of 1028
Crispr'd Cells Show Promise in First US Human Safety Trial

It’s been over three years since US regulators greenlit the nation’s first in-human test of Crispr’s disease-fighting potential, more than three years of waiting to find out if the much-hyped gene-editing technique could be safely used to beat back tough-to-treat cancers. Today, researchers from the University of Pennsylvania and Stanford finally revealed the first published report describing the trial. The highly anticipated results showed that the procedure is both safe and feasible; the Crispr’d cells went where they were supposed to go and survived for longer than expected. They didn’t cure anyone’s cancer, but they didn’t kill anyone, either, which means the results hold significant promise for the future of Crispr-based medicines.

Read More - Wired

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/18/2020 9:05:35 AM
1 Recommendation   of 1028
The messy, secretive reality behind OpenAI’s bid to save the world

The AI moonshot was founded in the spirit of transparency. This is the inside story of how competitive pressure eroded that idealism.

Every year, OpenAI’s employees vote on when they believe artificial general intelligence, or AGI, will finally arrive. It’s mostly seen as a fun way to bond, and their estimates differ widely. But in a field that still debates whether human-like autonomous systems are even possible, half the lab bets it is likely to happen within 15 years.

In the four short years of its existence, OpenAI has become one of the leading AI research labs in the world. It has made a name for itself producing consistently headline-grabbing research, alongside other AI heavyweights like Alphabet’s DeepMind. It is also a darling in Silicon Valley, counting Elon Musk and legendary investor Sam Altman among its founders.

Read More - $MIT Technology Review

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/18/2020 9:26:40 AM
1 Recommendation   of 1028
The Datacenter Has an Appetite for GPU Compute

It is not inconceivable, but probably also not very likely, that the datacenter business at GPU juggernaut Nvidia could at some point in the next one, two, or three years equal that of the core and foundational gaming sector. It is hard to tell based on current trends, and it all depends on how you extrapolate the two revenue streams from their current points and slopes and reconcile that against longer term data for the past six years.

The datacenter business at Nvidia was much smaller than the company’s OEM and IP businesses only a few years ago, and on par with its automotive segment until 2017, when GPU-accelerated HPC first really took off after a decade of heavy investment by the company and also when various kinds of machine learning had matured enough to for it to go into production at many of the hyperscalers and to be deployed as a compute engine on the large public clouds. Only four years ago, HPC represented about two-thirds of the accelerated compute sales for Nvidia’s datacenter products with the remainder largely dominated by early AI systems, mostly for machine learning training but also for some inference and also for experimentation with hybrid HPC-AI workloads. Now, as fiscal 2020 comes to a close in January, we infer from what Nvidia is saying about hyperscalers that AI probably represents well north of half of the datacenter revenue stream.

Read More – The Next Platform

Share RecommendKeepReplyMark as Last Read

From: Paul H. Christiansen2/18/2020 9:31:33 AM
1 Recommendation   of 1028
Robotic process automation is a big market, but there will be only one big winner

The market for robotic process automation is one of the hottest in tech right now, rapidly gaining traction as larger enterprises look to speed up their business processes by automating mundane office tasks.

A lot of the buzz around RPA comes from the massive amounts of money being injected into the market. The two biggest players in RPA right now, Automation Anywhere Inc. and UiPath Inc., are both startups that have raised almost $1 billion between them, sharing a combined market value of nearly $14 billion. Meanwhile, the market generated revenue of around $1 billion in 2019, almost double a year ago.

Read More - siliconANGLE

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10